HC Wainwright reaffirmed their buy rating on shares of Asensus Surgical (NYSEAMERICAN:ASXC – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $2.00 price target on the stock. HC Wainwright also issued estimates for Asensus Surgical’s Q4 2023 earnings at ($0.05) EPS, FY2023 earnings at ($0.30) EPS, Q1 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.18) EPS, FY2025 earnings at ($0.12) EPS, FY2026 earnings at ($0.07) EPS and FY2027 earnings at $0.04 EPS.
Separately, Cantor Fitzgerald reiterated an overweight rating and set a $1.00 target price on shares of Asensus Surgical in a research report on Tuesday, August 22nd.
Asensus Surgical Stock Up 5.4 %
Institutional Trading of Asensus Surgical
Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC raised its holdings in Asensus Surgical by 444.2% in the first quarter. FMR LLC now owns 48,584 shares of the company’s stock worth $32,000 after purchasing an additional 39,656 shares in the last quarter. BlackRock Inc. raised its holdings in Asensus Surgical by 1.2% in the second quarter. BlackRock Inc. now owns 3,699,987 shares of the company’s stock worth $1,868,000 after purchasing an additional 44,503 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Asensus Surgical in the first quarter worth about $31,000. Mirador Capital Partners LP raised its holdings in Asensus Surgical by 83.2% in the third quarter. Mirador Capital Partners LP now owns 110,000 shares of the company’s stock worth $30,000 after purchasing an additional 49,961 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Asensus Surgical by 58.5% in the fourth quarter. Renaissance Technologies LLC now owns 152,473 shares of the company’s stock worth $53,000 after purchasing an additional 56,300 shares in the last quarter. 10.06% of the stock is currently owned by institutional investors.
Asensus Surgical Company Profile
Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.
- Five stocks we like better than Asensus Surgical
- Find and Profitably Trade Stocks at 52-Week Lows
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- 3 Grocery Stocks That Are Proving They Are Still Essential
- MarketBeat Week in Review – 11/13 – 11/17
- Pros And Cons Of Monthly Dividend Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Asensus Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asensus Surgical and related companies with MarketBeat.com's FREE daily email newsletter.